ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical

Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed u

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raise

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Conse

On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earni

Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst cons

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the pri

Companies Reporting Before The Bell • MillerKnoll (NASDAQ:MLKN) is likely to report quarterly earnin

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (

AWM Investment Company Inc. bought a new stake in Aytu BioPharma Inc. (NASDAQ: AYTU) during the seco

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001385818/000143774926021707/aytu20260624c_8k.htm

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raise

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Conse

Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:

Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have received a consensus rating of "

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consen

Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch i

AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Na

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earni

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $